Blog

AusBiotech announces leadership changes

Mr Glenn Cross retires as AusBiotech’s CEO, and Ms Lorraine Chiroiu appointed as new CEO effective early July 2018 Mr Glenn Cross retirement AusBiotech Chairman, Julie Phillips, has tonight announced that Mr Glenn Cross has decided to retire…

Job: Director, Clinical Operations & Medical Affairs

Prota Therapeutics is an Australian private company developing immunotherapy based treatments for food allergy. The company’s lead product based on technology licensed from the Murdoch Children’s Research Institute, is under development as a treatment for the most common…

Bioforum Data Focused CRO Opens New Melbourne Office

Company provides local services for companies running R&D activities in Australia Bioforum – the Data Focused CRO and the leading Medidata partner in Israel, servicing research and academic institutes, pharma companies, CROs and startups locally and globally for…

$10m in funding awarded to 11 projects to boost health innovation

MTPConnect – the Australian Government’s Medical Technology, Biotechnology, and Pharmaceutical (MTP) Industry Growth Centre – and the Minister for Health, the Hon Greg Hunt MP, today announced the first 11 recipients of $10 million investment from the Australian…

Job – Technical Support Scientist – GENOMICS – ANZ

♦ Sequencing ♦ NGS | Genomics ♦ World leading technology Our Client Our client is a leading supplier of high technology solutions to the Australasian life sciences market. Their portfolio is representative of some of the best manufacturers…

Prota Therapeutics partners with world-leading bioscience company, Chr. Hansen

Prota Therapeutics partners with leading global bioscience company, Chr. Hansen, to progress the development of oral immunotherapies to treat food allergies. The partnership will assess the world’s best documented probiotic strain LGG® in a Phase III clinical trial…

Funding Announcement – Applications open for new round of Sector Growth Program

A new round of funding is now available under the Victorian Government’s Sector Growth Program, which offers up to $1 million to support projects that create jobs, and drive growth, productivity and competitiveness of local businesses. Eligibility requirements…

Future Plans Announced for Digital Health CRC

A $200+ million opportunity to transform health delivery: improving health outcomes; reducing waste in the health system; building businesses and jobs. The new Digital Health CRC (Cooperative Research Centre) will invest over $200 million to develop and test…

Cancer Therapeutics CRC Appoints New CEO

Cancer Therapeutics CRC (CTX), a small molecule oncology drug discovery and development group partnered with some of Australia’s pre-eminent medical research institutions, is pleased to announce the appointment of Brett Carter as Chief Executive Officer. Brett will succeed…

Immutep Raises A$6.85M Through Institutional Placement

Read ASX Announcement Here • A$6.85m raised through share institutional placement to drive immuno-oncology development programs • Placement of new ordinary shares to leading Australian healthcare institutional investors Platinum Asset Management and Australian Ethical Investment, U.S. healthcare institutional…

Immutep Enters Into Clinical Trial Collaboration and Supply Agreement with MSD

Read ASX Announcement Here Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) has announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as…

Home

News & opinion

Member Directory

Events